DENVER — In this video from the American Academy of Dermatology Annual Meeting, Brian S. Kim, MD, MTR, discusses the continued influx of novel therapies for atopic dermatitis treatment.
“So many new drugs came in for atopic dermatitis that many thought ‘okay, maybe this is the end of the road,’ but that doesn’t seem to be the case,” Kim, professor of dermatology and vice chair of research at Icahn School of Medicine at Mount Sinai and director of the Mark Lebwohl Center of Neuroinflammation and Sensation, told Healio. “The technologies and new developments are really breaking through.”
Sources/Disclosures
Source:
Healio Interviews
Disclosures:
Kim reports receiving consultant fees from AbbVie, AstraZeneca, Evommune, Guidepoint Global, Leo Pharma, Pfizer, Recens Medical, Regeneron, Sanofi and Septerna; serves on the advisory board for Almirall, Eli Lilly and Novartis; owns stock in Alys Pharmaceuticals and Locus Biosciences; and received research grant funding from Leo Pharma.
Ask a clinical question and tap into Healio AI’s knowledge base.
- PubMed, enrolling/recruiting trials, guidelines
- Clinical Guidance, Healio CME, FDA news
- Healio’s exclusive daily news coverage of clinical data
<
Leave a Reply